Viromed Medical Expands ViroCAP® Distribution to Six New Markets

Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced new distribution partnerships for its ViroCAP® product, expanding its presence into six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, and were signed with six separate companies, each responsible for a specific market. The partnerships include minimum purchase quantities, and based on these contracts, Viromed anticipates additional sales of at least 3,000 devices per year.

ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use by hospitals, private practice physicians, and surgically active medical specialists. The device has been a key product in Viromed's portfolio, and the company has been actively pursuing international expansion.

Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the development: “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks.”

These new agreements build on Viromed's existing international distribution network. The company already has numerous distribution and marketing partnerships, including an exclusive distribution agreement with the Korean company UMECO covering ten Asian countries, and a distribution partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. The expansion into Southern and South-Eastern Europe, as well as the Middle East, is a strategic move to increase market penetration and meet the growing demand for cold plasma technology in medical applications.

The significance of this announcement lies in Viromed's continued growth momentum. The company, which has been listed on the stock exchange since October 2022, is focused on commercializing cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. By securing these new distribution channels, Viromed is not only broadening its geographic reach but also ensuring a steady revenue stream from minimum purchase commitments. The expected sales of at least 3,000 devices per year represent a substantial increase in volume, which could contribute to the company's financial performance and market position.

Moreover, the partnerships signal confidence in ViroCAP®'s efficacy and market potential. Cold atmospheric plasma is an emerging technology in dermatology and wound care, and Viromed is positioning itself as a leader in this niche. The expansion into new territories is likely to increase brand awareness and create opportunities for further collaborations. As the company prepares to sign additional partnerships in the coming weeks, it is clear that Viromed is aggressively pursuing a growth strategy that could reshape its competitive landscape.